日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
2025/02/21 | 00 : 36 | GlobeNewswire Inc. | 60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/02/12 | 07 : 23 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/02/12 | 02 : 59 | GlobeNewswire Inc. | Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF® | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/02/07 | 06 : 41 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/02/07 | 04 : 07 | GlobeNewswire Inc. | 60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/02/07 | 00 : 04 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/02/05 | 23 : 22 | GlobeNewswire Inc. | 60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/01/31 | 07 : 30 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/01/31 | 04 : 20 | GlobeNewswire Inc. | 60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/01/30 | 22 : 28 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/01/29 | 22 : 00 | GlobeNewswire Inc. | 60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/01/29 | 06 : 05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/01/28 | 22 : 01 | GlobeNewswire Inc. | 60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/01/25 | 06 : 52 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/01/25 | 06 : 51 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/01/22 | 07 : 00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/01/22 | 06 : 58 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/01/09 | 06 : 05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2025/01/08 | 22 : 02 | GlobeNewswire Inc. | 60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2024/12/23 | 22 : 57 | GlobeNewswire Inc. | Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2024/12/19 | 10 : 35 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2024/12/11 | 22 : 56 | GlobeNewswire Inc. | 60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2024/12/10 | 07 : 07 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2024/11/22 | 08 : 14 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2024/11/15 | 04 : 31 | GlobeNewswire Inc. | 60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2024/11/15 | 03 : 44 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2024/11/07 | 07 : 26 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2024/10/16 | 04 : 46 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2024/10/08 | 21 : 17 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |
2024/10/03 | 22 : 02 | GlobeNewswire Inc. | 60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch | NASDAQ:SXTPW | 60 Degrees Pharmaceuticals Inc |